Skip to main content
Premium Trial:

Request an Annual Quote

Sygnis Signs Distribution Deal with BioCat for DNA Amplification Kit

NEW YORK (GenomeWeb) – Sample prep firm Sygnis today announced a non-exclusive deal with BioCat to distribute the True Prime Single Cell WGA kit for DNA amplification, Sygnis' first proprietary product.

The True Prime Single Cell WGA kit uses a novel multiple displacement amplification method to amplify total genomic DNA of single cells for next-generation sequencing. It will be the first in a series of TruePrime products for DNA or RNA amplification and is expected to be launched in January 2015, the firm said in a statement.

The agreement grants BioCat non-exclusive rights to promote, market, sell, and support the kit. Financial and other details of the deal were not disclosed.

"The superior features of TruePrime make it highly attractive for use in areas such as human genetics, oncology, or pathology, where researchers need to obtain biological information from the smallest amounts of samples," BioCat CEO Michael Ehret said in a statement. "This agreement will provide us with a product to more effectively address the fast growing market of next-generation sequencing."

With offices in Heidelberg, Germany and Madrid, Spain, Sygnis specializes in the development and commercialization of products for DNA amplification and sequencing. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.